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ABSTRACT 
Brucella abortus strain RBS l is the standard vaccine used against brucellosis in cattle and 
bison in North America. Five selective media currently used for isolating brucellae, four 
commercially available media used in isolating other Gram-negative bacteria, and two media 
developed in this study were compared to tryptose agar with 5% bovine serum (TSA) for 
supporting growth and influencing colonial morphology of RB51 . Four of the five media 
currently used for isolation of brucellae and two of the four media used in isolating other Gram-
negative bacteria did not support the growth of RBS l . Modified Kuzdas and Morse {MKM), 
Brilliant Green, Skirrow' s, and the developed selective media supported growth ofRBS l with 
typical rough colonial morphology. 
Recovery of Bruce/la abortus RB5 l was attempted on TSA, MKM, and the two 
developed selective media, B. abortus RB5 l (BRB) and brucellae malachite green medium 
(BMG) from tissues of vaccinated bison. The efficiency of each medium to control contaminant 
growth was determined. Female bison (n=20) were vaccinated with approximately 1.4 X 1010 
CFU ofRB51 at three to six months of age. At 14, 18, 22, 26, and 30 weeks post inoculation, 
four vaccinates were sacrificed and tissues were collected in an attempt to recover RBS l . RB5 l 
was recovered from 42 samples on TSA, 19 samples on MKM, 24 samples on BRB, and 38 
samples on BMG medium. RBS l was recovered on only one medium from 21 samples with the 
remaining media culture negative (9 on TSA; 3 on BRB; and 9 on BMG). Growth of 
contaminating bacteria prevented detection ofRBS l from 41 samples on TSA, 24 on MKM, three 
on BRB, and 25 on BMG. These data suggest that the use of BRB and BMG, in combination 
with TSA, enhances the recovery ofRBS l when processing bison tissues. 
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CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
Brucellosis, caused by Bruce/la abortus, continues to have an economic impact on the 
cattle industry (29) and has become a concern in free ranging bison in North America (7), even 
though vaccine strain 19 (29) has been used in the United States Brucellosis Eradication Program 
since the 1940s. Strain 19 only protects 65 to 75 per cent of vaccinates (22) and, because it is 
a smooth organism, can cause ambiguous results in standard serologic assays used in diagnosing 
field cases of brucellosis. In 1986, a mutant of B. abortus strain 23 08, designated strain RB5 l , 
was derived (69). After promising initial results (21, 72), RB51 was proposed to be used as a 
vaccine against bovine brucellosis. In 1996, RB51 was approved as the official calfhood 
brucellosis vaccine for cattle and has recently been used as a vaccine against brucellosis in bison 
(58). Vaccination with RB5 l induces cell-mediated immune responses and provides protection 
when challenged withB. abortus 2308 (21). Also, RB51 is lipopolysaccharide (LPS) 0-antigen 
deficient and does not induce production of antibodies that interfere with interpretation in 
serologic assays currently used for diagnosis of brucellosis in cattle (72). 
Brucellosis has become endemic in free-ranging bison in North America (7). It has been 
estimated that up to 20% of the female bison in Yellowstone National Park are infected. It has 
been shown that brucellae can be transmitted from bison to cattle (26). As ranged cattle 
encounter free-ranging bison around the national parks, there is potential for transmission of 
brucellosis from the infected bison to cattle. 
Recovery of brucellae from clinical veterinary samples often requires the use of selective 
media to reduce or eliminate growth of contaminants. There are several brucellae selective media 
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that are currently being used for this purpose. However, the ability of these media to support 
growth ofRB51 has not been evaluated. Because RB51 is being used to vaccinate cattle and 
bison, it is important that a selective medium be available on which RB51 can be recovered. 
The first objective of this study was to evaluate selective media currently used for isolation 
ofbrucellae for ability to support growth and influence colonial morphology ofRB51 . Included 
wereEwalt's (EWT) (31), Farrell's (FAR) (34), Kuzdas and Morse (KM) (44), modified Kuzdas 
and Morse (MKM) (3), and Brucel/a ovis medium (BOM) (16). Also evaluated were Brilliant 
Green Agar (BGA) (8), Improved Thayer-Martin (ITM) (50), Modified Thayer-Martin (MTM) 
(49), and Skirrow's medium (SKR) (70), which are commonly used for isolating other Gram-
negative bacteria. Two new selective media were developed and evaluated in this study. To 
determine components for the developed media, disk diffusion susceptibility and macrodilution 
broth tests were performed. 
Brucellae have been reported to be resistant to EDTA ( 51 ), malachite green ( 43 ), and 
rifampicin (69). These agents were also considered as potential components for the new selective 
media. From these data, two experimental media were developed and compared to tryptose agar 
with 5% bovine serum (TSA) for ability to support growth and influence colonial morphology 
ofRB51. 
Brucellosis has been identified as a significant problem in free-ranging bison and elk in and 
around the national parks (27, 29). The use ofRB51 in vaccinating bison would at times involve 
pregnant cows. It has been shown that RB51 can induce abortion and placentitis in pregnant 
bison (5) . Therefore, a selective medium on which RB51 can be isolated is essential. 
The second objective in this study was to compare TSA, MKM (2), and two recently 
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developed selective media, B. abortus RB51 (BRB) and brucellae malachite green (BMG) 
medium for efficiency to support growth of RBS I and inhibit growth of contaminants 
encountered in processing clinical veterinary samples from bison. 
This study demonstrated that most selective media currently used for isolation ofbrucellae 
inhibit the growth ofRB5 l and that the two media developed in the study support the growth of 
RB51 as well as TSA, while inhibiting the growth of contaminants better. 
Thesis Organization 
This thesis is prepared in the alternate format and includes two manuscripts prepared to 
be submitted to refereed scientific journals. The format used conforms to the American Society 
of Microbiology's ASM Style Manual for Journals and Books. A review of the literature 
precedes the first manuscript and a general discussion follows the last manuscript. Literature 
cited in each chapter appears at the end of the respective chapter. The candidate was the principal 
investigator and author for each manuscript presented. 
Literature Review 
History of Brucellosis 
Brucellosis has been described from antiquity. Sir David Bruce is credited with first 
reporting the responsible agent, which he called Micrococcus melitensis, in 1887 (17). He 
cultured the organism from the spleens of soldiers who had died of Malta fever. Bruce later was 
recognized for this, with the genus being named Bruce Ila. 
Bovine brucellosis was first reported in 1897 by Bang to be epizootic abortion of cattle 
(4). He identified it as Bacterium abortus and showed it responsible for the disease causing 
abortion in cattle by fulfilling Koch's postulates. Bang later described the pathology of Brucella 
- - - - - - - -
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abortus in cattle and suggested separating infected cattle from the herd as a deterrent for the 
spread of the disease (5). 
In 1911, Schroeder and Cotton ( 67) reported isolating brucellae from cows milk that was 
later confirmed by Fabyan to be B. abortus (33). It was shown in 1918 that the organisms 
described by Bruce and Bang were related morphologically and serologically and were placed in 
the same genus Bacterium melitensis (30). Buck later showed that Bacterium melitensis and B. 
abortus could be differentiated by their cultural and atmospheric requirements if recently isolated 
organisms were used (18). He showed that, while B. melitensis grew on serum-agar slants under 
normal atmospheric conditions, B. abortus required an atmosphere partially displaced by C02. 
Brucellosis Eradication Program 
Bang reported in 1906 that cattle exposed to virulent B. abortus developed immunity (5). 
At his recommendation, heifers were infected with B. abortus before breeding, causing a 
significant reduction in the abortion rate. However, there was no oversight of the vaccinations 
and uncontrolled amounts of strains of differing virulence were used, sometimes causing disease. 
In 193 0, Buck reported results of a study in which he used an avirulent strain of B. 
abortus for calfhood vaccination. The organism, termed strain 19, had originally been isolated 
in 1923 from bovine milk as a virulent strain of B. abortus and had become attenuated after being 
left at room temperature for over a year (19) . 
In 1936, the first field trials were began, using live B. abortus strain 19 and by 1940 
efficacy studies supported the use of strain 19 as a vaccine to prevent Bang' s disease. In 1941, 
strain 19 was introduced and used in 3 9 states. 
In 1949, the National Brucellosis Committee (NBC) was organized. In 1954, Congress 
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approved funds for an accelerated program and the NBC set a goal that the United States 
become a modified certified brucellosis free nation by 1960 and certified brucellosis free by 1965. 
This goal was not met, and there began to be doubts about the feasibility of eradication of 
brucellosis. In 1972, another date for total eradication was set for December 31 , 197 5. This goal 
too was unmet. The most recent goal for eradication of bovine brucellosis from the United States 
is December 31 , 1998. 
Brucellae 
Taxonomy 
Brucellae are found in the order Eubacteriales and the family Brucellaceae. Genomic 
studies based on 16S rRNA show a close relationship of Brucella with Agrobacterium and 
Rhizobium (28). DNA-DNA hybridization studies link all brucellae to a single genospecies, B. 
melitensis (23). Classical nomenclature utilizes natural host preference and cultural, 
biochemical, and serological phenotypic characteristics. According to this nomenclature, there 
are currently six species of Brucella. B. abortus contains seven recognized biovars (1-6, and 
9), B. melitensis contains three (1-3),and B. suis contains five (1-5) (9, 25). B. ovis, B. canis, 
and B. neotomae each contain a single strain. Recently, Brucella was isolated from marine 
animals (32, 66). It has been recommended that these isolates be designated as a new 
nomenspecies (24). 
Morphology and Physiology 
Brucellae are gram-negative coccobacilli, 0.5-0.7 µmin diameter and 0.6-1.5 µmin 
length arranged singly, in pairs, or less often in short chains. They are non-motile, aerobic, 
exhibiting a oxidative metabolism, have a cytochrome-based electron transport system with 
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oxygen or nitrate as the terminal electron acceptor, and do not produce a true capsule. Brucella 
do not show true bipolar staining, have no known resting stages, produce nitrate reductase, are 
catalase, oxidase, and urease positive. They are citrate and methyl red negative, and produce 
H2 S. Differentiation of the six species is accomplished by phage typing, oxidative metabolic 
tests, slide and tube agglutination tests, and genetic probes. Also, C02 requirement, H 2 S 
production, and growth on media containing the dyes basic fuchsin and thionin are used to 
differentiate B. abortus, B. meletinsis, and B. suis. 
Brucellae are chemoorganotrophic and usually require complex media, although some 
strains will grow on minimal media with ammonium salt as the sole nitrogen source. Serum 
improves the growth of Brucella while hemin and NAD are not necessary. Pinpoint colonies 
appear on agar after 2-3 days incubation and grow to 2-3 mm diameter at five days. Growth 
is slower and reduced on selective media. Some strains require incubation in C02 for growth, 
especially for primary isolation. Optimal growth conditions are at a temperature of 37°C (20-
400C) and pH 6.6-7.4. On nutrient agar, by obliquely reflected light, colonies appear 
transparent, raised, convex, with an entire edge, a smooth, shiny surface, and a pale honey color. 
Brucella have a guanine+ cytosine (G+C) content of 56 mole per cent (9, 25) and have a 
double-stranded genome approximately 3,130 kb in size (1). Brucella melitensis has two 
independent chromosomes of 2.1 and 1.5 Mb, respectively ( 42, 52). Plasmids have not been 
detected in Brucella, although transformation has been reported in B. abortus (62) . 
Virulence Factors 
Virulence in Bruce Ila is in closely linked to the ability of the organism to survive and 
multiply intracellularly. Brucella possessing a smooth LPS (S-LPS) tend to be more virulent. 
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Brucella LPS does not induce interferon-y or tumor necrosis factor-a . These lymphokines are 
primarily responsible for eliminating Brucella via activated macrophages (76). Macrophages 
and neutrophils ingest smooth brucellae slower than do rough brucellae (63) . Production of 
adenine and guanine monophosphate, which inhibit phagocyte function, is another virulence 
determinant (20). Stress proteins have also been reported as virulence factors within 
macrophages (46, 47). Also, the ability to eliminate reactive oxygen intermediates within 
phagocytes by a Cu-Zn superoxide dismutase is a suspected virulence factor (12). 
Epidemiology 
Brucellae tend to host specific. The natural host for Brucella abortus is cattle. Dogs 
normally harbor Brucella canis, goats harbor B. melitensis, B. neotomae infects the desert 
woodrat (Neotoma lepida), sheep harbor B. ovis, and swine normally are the natural host for 
B. suis. Dogs can be reservoirs of B. abortus, B. melitensis, and B. suis if they come in contact 
with infected animals. Also, bison and camels can become infected with B. abortus and caribou 
with B. suis. Man can be infected with B. abortus, B. canis, B. melitensis, and B. suis. 
Infection is usually the result of contact with infected animals or their milk, milk products, or 
meat. Infection occurs through the gastrointestinal tract, skin, or mucous membranes. Local 
lymph nodes are infected and onset ofbacteremia. In pregnant or lactating animals, Brucella 
tends to multiply in the uterus and mammary glands. Brucellae localize in chorionic epithelial 
cells, causing necrosis of the placental cotyledons. Infection of the fetus can occur or abortion 
from asphyxia. 
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Diagnosis 
Recovery of Brucella from clinical specimens requires vigilant, well trained laboratory 
personnel. For primary culture, specimens are directly inoculated onto solid medium such as 
tryptose agar, trypticase soy agar, or brucella agar, each with serum. Plates are incubated in 
an atmosphere of 5% to 10% C02 at 37°C. Brucellae appear as pinpoint colonies at 3 days, and 
plates are observed for up to six weeks. When processing specimens, which may be heavily 
contaminated, selective media is also used. Suspect colonies are further characterized by Gram 
stain, oxidase test, fermentation of lactose or glucose and agglutination in unabsorbed anti-
smooth Brucella serum. 
Brucella abortus Strain RB5 l 
In 1991, Dr. Gerhardt Schurig described a stable rough strain of B. abortus designated 
RB51, which had been developed in his laboratory in 1986 (69). The mutant was derived by 
serial passage of B. abortus Strain 2308 on trypticase soy agar supplemented with 1.5% agar 
and varying concentrations of rifampin or penicillin. RB5 l showed reduced virulence in mice 
and failed to absorb a monoclonal antibody specific for the perosamine 0-side chain of B. 
abortus. Also, RB5 l protected mice from infection upon challenge with virulent B. abortus 
Strain 2308. 
Experimental infection of the fetuses of three pregnant goats each carrying twins with 
RB5 l failed to induce placental infection or abortion but caused production of significant levels 
oflgG in the does and infection of 50% of the kids (65). Fetuses were inoculated in utero by 
intramuscular injection at approximately 120 days gestation with 2.3 X 108, 4.3 X 107, and 8.6 
X 107 CFU of B. abortus RB5l respectively. Two fetuses of the first goat yielded RB51 in 
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tissues sampled. One kid of the second goat was infected, and neither of the kids of the third 
goat were infected. 
Tobias demonstrated that RB51 was less virulent than Strain 2308 and Strain 19 in 
pregnant mice (75). Pregnant BALB/c mice were given various doses of strain 19, 2308, and 
RB51. Lesions similar to those produced by 105·7 2308 organisms were produced by 105 
organisms of strain 19. Strain RB51 failed to produce similar lesions at a dose of 109·5 
organisms. The titer of the sera from RB51 infected mice remained negative, whereas infected 
mice showed seroconversion in the serum agglutination test. 
A study was conducted to determine the immune responses elicited and ability to protect 
against infection and abortion in cattle using RB51 as a vaccine. (21). Twenty four 10 month-
old heifers were inoculated SC with 1to1.4 X 101° CFU ofRB51, bred at 16 to 19 months, 
challenged-exposed during the fifth month of pregnancy, and necropsied immediately after 
abortion or parturition. Because RB5 l does not react in standard serological tests, a dot-blot 
assay was developed and used to determine the serologic responses in this study. RB5 l 
produced antibody responses in the vaccinates and their calves. RB51 offered protection from 
abortion after conjunctiva! exposure to 106 CFU of virulent B. abortus 2308. 
In 1995, Jensen reported that RB51 could be differentiated from B. abortus biovar 1, 
type Strain 544, and vaccinal Strains 19 and 45/20 by pulsed-field gel electrophoresis (41). Xba 
I digests ofbrucellae genomic DNA produced unique restriction endonuclease patterns useful 
for characterization of RB51 . The method allowed differentiation of RB51 from B. abortus 
isolates from naturally infected cattle, bison, and elk. 
A PCR assay has also been developed which can differentiate B. abortus vaccine strains 
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19 and RB51 (11). An eight primer cocktail contained a 364-bp product used for identification 
ofRB51 and a oligonucleotide primer pair was used to identify strain 19. 
In 1993, RB51 was used to vaccinate 3-month-old bison to determine serologic 
responses and persistence within lymph nodes (58). RB51 persisted in vaccinate lymph nodes 
at 16 weeks and, though antibodies to RB5 l were present, standard serologic assays remained 
negative. In 1996, RB51 was approved as the official calfhood brucellosis vaccine for cattle. 
Media for the Isolation ofBrucellae 
Basal Media 
Sir David Bruce used a peptone-beef infusion agar medium in 1887 to isolate B. 
melitensis from the spleens of soldiers who had died of malta fever (17). Bang ( 4) first isolated 
B. abortus from an aborted bovine fetus on a semi-solid gelatin agar supplemented with 33% 
serum. He observed a dense zone of growth approximately 2 mm below the surface of the 
medium. He attributed the failure ofNocard to fulfill Koch's postulates to the fact that "he was 
not in possession of an appropriate nutritive medium, since he did not add blood serum to the 
substances which he employed." 
After many years of noting lesions in the spleens of guinea pigs inoculated with cow's 
milk, Schroeder and Cotton in 1911 isolated an organism on agar with 6% glycerine and 5% ox 
bile (68). Later that year, they and Mohler showed that the organism was B. abortus (53, 67). 
Giltner (36) added uterine wall, fetal membranes, fetal tissue, or amniotic fluid to fresh 
chopped meat medium. He found that adding 1.5% agar to the medium containing amniotic 
fluid produced a suitable propagation medium. 
In 1920, Stafseth (71) substituted the beef with spleen or liver and observed better 
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growth. He also added 1 % starch or dextrose to the media and noted that growth was 
improved in the spleen medium after addition of carbohydrates, but the liver agar did not require 
them. He noted "Some strains have been found to possess certain idiosyncrasies, thus making 
it necessary to employ various media in order to find one that will produce the desired results." 
Selective Media 
Huddleson used Stafseth' s beef liver medium as a basal medium in which he 
incorporated the aniline dye gentian violet at 1:10,000 (37, 40). He found that the dye inhibited 
most Gram-positive organisms, yet allowed the growth ofbrucellae. Huddleson is credited for 
greatly simplifying the isolation process (38). Huddleson also used dyes to differentiate B. 
abortus and B. melitensis (39). 
In 1953, Kuzdas and Morse reported the development of a selective medium for 
isolation ofBrucellae from contaminated materials (44). To a basal medium of Albimi Brucella 
agar, polymyxin B (6 U/ml), actidione (100 µg/ml), bacitracin (25 U/ml), circulin (15 U/ml), and 
crystal violet (1 .4 µg/ml) were added. When compared with several other selective media, the 
developed selective medium was more effective in inhibiting contaminants. 
Morris (55) used 5-nitrofurfurylmethyl ether, bacitracin, polymyxin, and actidione in a 
basal medium oftryptose agar or modified Hartley digest agar. Brucellae colonies were smaller 
on the selective media than those grown on control agar. 
In 1960, a basal medium containing 0.5% Tween 40 instead of serum and the 
antimicrobial agents bacitracin, polymyxin, actidione and ethyl violet was compared to several 
other selective media for the ability to support growth and isolate B. abortus from milk of 
experimentally infected cows (13). The Tween containing media was as effective as the other 
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media tested in ability to isolate B. abortus 544 but would not support the growth of the B. 
abortus biotype 2. 
Painter et al. (59) compared different combinations of basal media, supplements, and 
antimicrobial agents for ability to isolate B. abortus, B. melitensis, and B. suis from infected 
animal tissues. They observed that, when tissues were the source of brucellae, there were 
greater differences in the ability of the media to support growth than if in vitro propagated 
strains were used. 
A selective medium for Brucella ovis was developed by Brown et al. in 1970 (16). 
Several combinations of antimicrobial and enrichment agents were incorporated into TSA or 
Thayer-Martin selective medium and evaluated for ability to support growth of B. ovis and 
control contaminants commonly found in ram semen. A modification of Thayer-Martin medium 
was found to be the most effective medium. 
Brodie and Sinton (15) developed fluid and agar media for isolating B. abortus. The 
fluid medium contained oxoid tryptone soya broth (CM129) with 5% sterile horse serum as the 
base. The inhibitory agents were minor alterations of Payne' s modification of Farrell' s medium 
(14) with the addition of cycloserine. The fluid enrichment technique allowed a 10-16% 
increase in recovery of B. abortus from bovine milk as compared to only plating milk on agar 
media. 
Robertson et al.(64) published a review of many of the then to date developed selective 
media. In this review, the authors show how, by conducting a systematic study ofbrucellae 
susceptibilities to antimicrobial agents, selective media can be developed that provide primary 
isolations without the need for animal inoculations. 
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Skirrow medium has been shown to support the growth of brucellae (73). While 
attempting to isolate Campylobacter fetus from fetal bovine abomasum contents, the authors 
isolated B. abortus biovar 1. They noted that growth of B. abortus was faster and more prolific 
on Skirrow medium than on Farrell's medium. 
A modified Farrell's medium was used by Radwan (61) to isolate Brucella from the milk 
of one-humped camels in Saudi Arabia. The selective medium consisted of brain heart infusion 
agar with 5% defibrinated sheep blood, 1 % sterile dextrose, and Farrell's antimicrobial agents. 
Using the selective medium, B. melitensis was isolated from the milk of 26of100 brucellosis 
seropositive camels. 
B. melitensis was reported (35, 43) to grow on Loewenstein-Jensen egg medium. A 
major component of this medium is malachite green, a basic dye with bacteriostatic and 
antifungal activity. B. melitensis colonies appeared at two weeks as irregularly shaped mucoid 
colonies that proved non-acid-fast and were disregarded as contaminants. The authors 
recommended that any non-acid-fast "contaminant", which grows on Loewenstein-Jensen egg 
medium, should be investigated further. 
In 1996, Marin compared the efficacy of Farrell's medium (34) and modified Thayer-
Martin's medium (16) for the isolation of B. melitensis from naturally infected sheep and goats 
(48) . The modified Thayer-Martin's medium consisted of GC medium base (Difeo), 
haemoglobin (IO g/L) (Difeo), colistin methanesulphonate (7.5 mg/L), vancomycin (3 mg/L), 
nitrofurantoin (IO mg/L) and nystatin (12,500 units/L) (Sigma). Farrell's medium was prepared 
with brucella medium base (Oxoid; Unipath), 5% bovine serum and a commercial freeze-dried 
selective supplement (Oxoid). Modified Thayer-Martin's medium was shown to be more 
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sensitive, detecting more infected sheep. However, the combined use of both media yielded the 
largest number of infected specimens and animals. 
Development of Selective Media for the Isolation of Brucellae 
A selective medium must contain agents which inhibit the growth of contaminant 
organisms and allow the growth of the desired organism. Most selective media have five 
components: a basal medium, an enrichment component, an antifungal, a Gram-positive 
inhibitor, and a Gram-negative inhibitor. 
In the case of selective media for brucellae, the basal medium used most often is tryptose 
agar. In addition, blood agar, tryticase soy agar, and various nutrient agars have also been used. 
The enrichment component is usually bovine or equine heat inactivated serum or defibrinated 
blood. Antifungals used include; amphotericin B (45), anisomycin (50) cycloheximide (55), and 
nystatin (74). The Gram-positive inhibitors in brucellae selective media include: bacitraicn, 
(31), vancomycin (34), lincomycin (31). Gram-negative inhibitors which have been included 
in brucellae selective media are: colistin (16, 49, 74), nalidixic acid (34), and polymyxin B (31 , 
34, 44, 70). 
Components of Developed Selective Media 
Aztreonam is a beta-lactam antibiotic that exhibits activity exclusively against Gram-
negative bacteria (6) . It inhibits most Enterobacteriaceae at less than 2 µg/ml (57). However 
it is less active against nonfermenting bacteria (60). These two characteristics made aztreonam 
a possible replacement for polymyxin B in the developed medium as an inhibitor of Gram-
negative organisms. 
Brucella melitensis has been reported to grow on Loewenstein-Jensen Egg medium (35, 
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43). A chief component of this medium is the dye, malachite green. Because malachite green 
inhibits most microorganisms except Pseudomonas spp., mycobacteria, and some fungi (10), 
it was investigated as a potential component of the developed selective medium. 
Brucellae are resistant to the ethylenediaminetetraacetic acid (EDTA) (51, 54). EDTA 
destabilizes the outer membrane (OM) of a wide range of Gram-negative bacteria by first 
binding to OM anionic targets and rendering the cell envelope permeable and susceptible to lytic 
enzymes This, in tum, blocks cell functions that are dependent on membrane integrity. Work 
done by Martinez De Tejada demonstrated that even rough brucellae were more resistant to a 
concentration of 200 µg/ml of EDTA than Escherichia coli. EDTA reduced the growth of E. 
coli by 97% whereas growth of rough B. abortus Strain 45/20 was only reduced by 2.6%. 
Because of these properties, EDTA was also investigated as a potential component of the 
developed selective medium. 
Fluconazole is an antifungal compound in the azole class (56). The azoles inhibit fungal 
cytochrome P-450-dependent enzymes. This hinders ergosterol synthesis and causes the fungal 
cell membrane to be depleted oflevels of this vital sterol. Fluconazole, is a triazole with a broad 
antifungal spectrum. It is being used as an alternative to amphotericin B and ketoconazole in 
the treatment ofhistoplasmosis in AIDS patients. because of its being potentially less toxic in 
man. For this reason, fluconazole was evaluated for use as an antifungal in the developed 
selective media. 
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CHAPTER 2. EVALUATION OF SELECTIVE MEDIA FOR GROWTH OF BRUCELLA 
ABORTUS STRAIN RB51 
A paper to be submitted to Journal of Clinical Microbiology 
Richard L. Homsby1' 2, Allen E . Jensen2, and Charles 0 . Thoen3 
Abstract 
Eleven selective media, including five selective media routinely used for isolating 
brucellae, four commercially available media used for isolating other Gram-negative bacteria, and 
two media developed in this study were compared to tryptose serum agar for supporting growth 
and influencing colonial morphology of Brucella abortus strain RB51 . Modified Kuzdas and 
Morse, Brilliant Green, Skirrow' s, and the two developed selective media supported growth of 
RB51 with typical rough colonial morphology. Four of the five media used routinely for the 
isolation ofbrucellae and two of the four media used in isolating other Gram-negative bacteria 
did not support the growth ofRB51 . The inhibitory component in these media was determined 
to be polymyxin B or E. Components of the two new media were determined from results of 
susceptibility assays and from previous reports. Brucella abortus RBS I medium contained 
bacitracin (25 U/ml), cycloheximide (100 µg/ml), nystatin (100 µg/ml) , rifampicin (200 µg/ml), 
trimethoprim (5 µg/ml), and vancomycin (20 µg/ml) . Brucellae malachite green medium 
contained aztreonam (5 µg/ml) , cycloheximide (100 µg/ml) , EDTA (100 µg/ml), and malachite 
green (1 µg/ml) . 
Introduction 
Brucellosis, caused by Brucella abortus, continues to have an economic impact on the 
cattle industry (8) and has become a concern in free ranging bison in North America (3). Brucella 
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abortus strain 19 has been used for calfhood vaccination against brucellosis in the United States 
Brucellosis Eradication Program since the 1940s. Recently, a laboratory derived mutant of B. 
abortus strain 2308, designated RB5 l (22), has been used as a vaccine against brucellosis in 
cattle (7) and bison (21 ), and was approved in the United States for calfhood vaccination against 
brucellosis in cattle. Vaccination using RB5 l induces cell-mediated immune responses and 
provides protection from abortion when challenged with strain 2308 (7). Also, RB5 l lacks 
lipopolysaccharide (LPS) 0-antigen and does not induce production of antibodies that cause 
ambiguity in serologic assays currently used for diagnosis of brucellosis in cattle (24). 
Recovery of brucellae from veterinary samples often requires utilization of selective media 
to reduce or eliminate growth of contaminants. Several selective media are currently used for 
the isolation of brucellae from clinical samples, however, the ability of these media to support 
growth of RB5 l has not been evaluated. The induction of a protective cellular immune response 
against B. abortus requires the vaccine to survive in the regional draining lymphatics of cattle for 
a period of time (6). As RB51 is used to vaccinate cattle and bison, it is imperative that selective 
media be available which promotes growth ofRB51 so that the survival of the vaccine can be 
accessed. 
This study was designed to compare selective media currently used for isolation of 
brucellae to tryptose agar containing 5% bovine serum (TSA) for ability to support growth and 
influence colonial morphology ofRB51. Included were Ewalt's (EWT) (9), Farrell' s (FAR) (10), 
Kuzdas and Morse (KM) (13), modified Kuzdas and Morse (MKM) (1), and Bruce/la ovis 
medium (BOM) (5) . Also evaluated were Brilliant Green Agar (BGA) ( 4), Improved Thayer-
Martin (ITM) (15), Modified Thayer-Martin (MTM) (14), and Skirrow's medium (SKR) (23), 
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that are routinely used for isolating other Gram-negative bacteria. Another objective of this study 
was to develop new selective media which would support the growth of RB5 l. Because 
brucellae have been reported to be resistant to EDTA (16), malachite green (12), and rifampicin 
(22), these agents were considered potential components for the new selective media. Other 
components were included as based on results from disk diffusion susceptibility and macrodilution 
broth dilution tests. The two new selective media, Bruce/la abortus RB5 l (BRB) medium, and 
brucellae malachite green (BMG) medium, were compared to TSA for their ability to support 
growth and influence colonial morphology of RB5 l. 
Materials and Methods 
Bacteria and cultivation. Bruce/la abortus vaccine RB5 l (22) was obtained from Colorado 
Serum Company (Denver, CO). Derivatives of RB5 l were also evaluated and included ARS/l, 
1311 (high passage), 1303 (from bovine blood), and 1492 (from bison vaccinate). Bruce/la 
abortus biovar 1 strains 1146 (from elk), 1137 (from bison), 2308, and strain 19, and the type 
strainsB. abortus 544, B. canis RM-666, B .melitensis 16M, B. neotomae 5K33, B. ovis 631290 
and B. suis 1330 were from brucellosis culture collection at National Animal Disease Center 
(Ames, IA). Escherichia coli (ATCC® 25922), Staphylococus aureus-aureus (ATCC® 25923), 
and Pseudomonas aeruginosa (ATCC® 27853) were obtained from American Type Culture 
Collection (ATCC, Rockville, MD). Cultures were initially grown on TSA Plates were 
incubated at 37°C in air or 5% C02. Cultures were examined for colonial morphology using the 
method described by Henry (11 ), and for typical growth characteristics (2) before use. 
Susceptibility tests. Disk diffusion tests were performed using brucellae and controls 
(Escherichia coli, S. aureus-aureus, and P. aeruginosa) as described (20). Briefly, Mueller-
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Hinton agar plates (Difeo) supplemented with 0.5% yeast extract (Difeo) and 5% bovine serum 
were inoculated using a sterile cotton swab with a spectrophotometrically adjusted suspension 
from a 24 h growth of control organisms or a 48 h growth ofbrucellae. Disks containing the 
antimicrobial agents azlocillin (75 µg) , aztreonam (30 µg) , bacitracin (10 U), cefoperazone (75 
µg), cephalothin (30 µg), chloramphenicol (30 µg), cinoxacin (100 µg), clindamycin (2 µg) , 
colistin (10, 30 µg), erythromycin (15 µg), imipenim (10 µg), kanamycin (30 µg), lincomycin (2 
µg), nalidixic acid (30 µg) , nitrofurantoin (300 µg) , novobiocin (30 µg) , nystatin (100 U), 
penicillin G (10 U), piperacillin (100 µg) , polymyxin B (300 U), rifampicin (5 µg) , streptomycin 
(10 µg) , tetracycline (30 µg) , ticarcillin/ clavulanic acid (75/10 µg) , 
trimethoprim/sulfamethoxazole (1 .25/23 .75 µg) , triple sulfa (300 µg), vancomycin (30 µg) were 
obtained from Difeo Laboratories (Detroit, :MI). Disks containing azithromycin ( 15 µg), cefixime 
(5 µg) , cefotaxime (30 µg), ceftizoxime (30 µg) , ciprofloxacin (5 µg) , clarithromycin (15 µg) , 
enoxacin (10 µg), lomefloxacin (10 µg), and ofloxacin (5 µg) were obtained from Remel (Lenexa, 
KS). Antimicrobial disks were dispensed onto the surface of the agar and each disk pressed down 
with sterile forceps to ensure complete contact with the agar surface. Plates were inverted and 
incubated at 3 7°C in air or 5% C02. At 24 h, plates were observed above a black background and 
zones of inhibition were measured. Organisms were reported as either susceptible, intermediate, 
or resistant to the agents tested 
Macrodilution broth MICs were determined as described (19) for aztreonarn, brilliant 
green, erythromycin, malachite green, nalidixic acid, polymyxin B sulfate, rifampicin, and 
trimethoprim (Table 2). Mueller-Hinton broth (Difeo) with 0.5% yeast extract and 5% bovine 
serum containing two-fold dilutions from 1 to 1024 ug/ml or U/ml of the antimicrobial agents was 
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inoculated with a 48h growth of brucellae to obtain a suspension of 5 X 105 CFU/ml. Tubes were 
incubated at 37°C in air (RB51) or 5% C02 (B. abortus biovar 1 field isolates, 544 and B. ovis). 
Tubes were visually evaulated at 48 h, and the :MIC was recorded as the lowest concentration of 
antimicrobial agent in which growth was not detected. Combinations of the antimicrobial were 
also evaluated for synergist effects and to determine the concentration at which combinations 
could be incorporated into new selective media. 
New selective media. Two selective media were developed by incorporating into TSA 
combinations of components determined from the disk diffusion and broth dilution data and 
previous reports of antimicrobials on brucellae (10, 12, 17, 22, 23). Evaluation of selective 
media. Formulations of selective media are shown in Table 1. Ten replicates of each medium 
were inoculated with 0.5 ml ofa 0.15% NaCl solution containing 200 CFU/ml ofRB51. The 
inoculum was spread over the agar surface by rocking. Plates were incubated for 24 h, then 
inverted and incubated for an additional 3 d. Colonies were counted by surface viable count (18) 
and colonial morphology was determined using obliquely reflected light (11 ). Media that did not 
support the growth of RB51 at this level were further evaluated to determine the minimum CFU 
that each would support using 1 Ox concentrations of RB51. Student's T- test was used to 
compare growth of RB51 on selective media to TSA. 
Results 
Susceptibility assays. In disk diffusion tests, all Brucella spp. tested were resistant to aztreonam, 
bacitracin, lincomycin, nystatin, trimethoprim, and vancomycin. Strain RB5 1 was also resistant 
to clarithromycin, erythromycin, clindamycin, nalidixic acid, and rifampicin. Brucella abortus 544 
was also resistant to azithromycin, clarithromycin, clindamycin, colistin, and triple sulfa. 
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Antimicrobial agents to which brucellae were either sensitive or intennediate to were not further 
evaluated. Results using Escherichia coli , S. aureus-aureus, and P. aeruginosa were consistent 
with National Committee for Clinical Laboratory Standards (NCCLS) guidelines. 
Macrobroth dilutionMICs (Table 1). for B. abortus strains RB51and544 were 8 µg/ml 
for malachite green, 16 for aztreonam, erythromycin, and nalidixic acid, and 64 for trimethoprim. 
The MI Cs for RB51 and 544 were 4 and 2 for brilliant green, 4 and 32 for polymyxin B sulfate, 
and 1024 and <1 µg/ ml for rifampicin respectively 
Evaluation of selective media. The MKM and SKR media supported growth of RB51 as well as 
TSA (p > 0.05) (Table 3). Growth ofRB51 on BGA was significantly lower (p < 0.01) than 
TSA. The BOM, EWT, FAR, KM, ITM, and MTM media did not support growth ofRB51 
when inoculated with 100 CFU (Table 3).The minimal numbers ofRB51 required for growth on 
these media were: 1X105 CFU for BOM, 1X103 CFU for EWT, 1X106 CFU for FAR, 1 X 
106 CFU for ITM 1 X 104 CFU for KM, and 1 X 106 CFU for MTM. 
New selective media 
The BRB medium contained bacitracin (25 U/ml), cycloheximide (100 µg/ml) , nystatin (100 
U/ml), rifampicin (200 µg/ml) , trimethoprim (5 µg/ml) , and vancomycin (20 µg/ml) . The BMG 
medium consisted of aztreonam (5 µg/ml), cyclohex.imide (100 µg/ml) , EDTA (100 µg/ml) , and 
malachite green (1 µg/ml) . Both media supported the growth ofRB5 l as well as TSA (p = 0. 777 
and 0.459, respectively) (Table 3). The colonial morphology of RB51 on BRB was similar to 
colonies grown on TSA; however, colonies grown on BMG appeared more granular. 
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Discussion 
Selective media provides for an increased number of isolations ofbrucellae from field 
samples as compared to TSA because samples taken in the field are often contaminated and TSA 
contains no antimicrobial agents. Of the five media tested that are currently used for recovery 
of brucellae, four did not support the growth ofRB5 l. This study shows that MKM and SKR 
media support the growth of RB5 l as well as TSA. However, .MKM contains antimicrobials at 
a low level and there is potential for contamination problems. SKR medium contains blood in the 
basal medium which makes identification of brucellae difficult. The two experimental media, 
BRB and BMG, support the growth of RB5 l as well as TSA, and inhibit the growth of 
contaminants better than .MKM. 
The MIC data show that RB5 l is inhibited at 4 U/ml. of polmyxin B. EWT and FAR 
contain 5 U/ml of polymyxin B, and KM contains 6 U/ml. This would account for the inhibitory 
effect of these media as MKM and SKR media both contain lower amounts of polymyxin B (1.8 
and 2.5 U/ml respectively) and do support growth of RB51 . The BOM, ITM, and MTM contain 
colistin (polymyxin E), the inhibitory agent in these media. If the level of polymyxin B or E is 
reduced in these media, there will be problems with contamination. Therefore, another agent 
which would inhibit Gram-negative bacteria but not brucellae, especially RB5 l was needed. 
This study showed six possible agents, aztreonam, EDT A, erythromycin, malachite green, 
nalidixic acid, and rifampicin could be used in developing a selective medium that supported the 
growth of RB51 and inhibited growth of contaminants commonly encountered in the processing 
of clinical samples. Various combinations of these agents with Gram-positive bacterial inhibitors 
and antifungals were evaluated for ability to support growth and influence colonial morphology 
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ofRBS 1. Media containing erythromycin or nalidixic acid did not support growth of RBS 1. The 
other four antimicrobials were incorporated into the two developed media, one on which field 
strains of B. abortus and RBS 1 can be isolated (BMG) and a differential medium (BRB) which 
only supports the growth ofRBS l . These two media are currently being evaluated for recovery 
of RBS 1 from vaccine field studies done in bison and cattle. These studies have shown that BRB 
which contains the broad spectrum antimicrobial rifampicin is more effective than BMG for 
inhibiting contaminants but BMG is more effective in isolating RBS l . Based on these 
observations, it is recommended that BRB and BMG be used in combination with TSA when 
attempting isolation ofbrucellae from field specimens. 
References 
1. Alton, G. G., L. M. Jones, RD. Angus, and J.M. Verger (Eds.). 1988. Techniques 
for the brucellosis laboratory. Institut National de la Recherche Agronomique, Paris. 
2. Alton, G. G., L. M. Jones, RD. Angus, and J.M. Verger (Eds.). 1988. Techniques 
for the brucellosis laboratory. Institut National de la Recherche Agronomique, Paris. p. 
34. 
3. Baskin, Y. 1997. Study shows one-fifth of female bison infected. Science 276: 1786. 
4. BBL. 1968. Manual of Products and Laboratory Procedures. 5th ed. BBL 
Microbiology Systems, Division of Becton Dickinson and Company, Cockeysville, MD. 
p. 95 . 
5. Brown, G. M., C. R Ranger, and D. J. Kelley. 1971. Selective media for the isolation 
of Bruce/la ovis. Cornell Vet. 61:265-280. 
6. Cheville, N. F., A. E. Jensen, S. M. Halling, F. M. Tatum, D. C. Morfitt, S. G. 
Hennager, W. M. Frerichs, and G. Schurig. 1992. Bacterial survival, lymph node 
changes, and immunologic responses of cattle vaccinated with standard and mutant strains 
of Bruce/la abortus. Am. J. Vet. Res. 53: 1881-1888. 
31 
7. Cheville, N. F., M. G. Stevens, A. E. Jensen, F. M. Tatum, and S. M. Halling. 1993. 
Immune responses and protection against infection and abortion in cattle experimentally 
vaccinated with mutant strains ofBrucel/aabortus. Am. J. Vet. Res. 54:1591-1597. 
8. Estipona, A., R. E. Mason Jr., and J. A. Young. 1989. Brucellosis-A range livestock 
problem. Rangelands 11: 17 4-17 6. 
9. Ewalt, D.R., R. A. Packer, and S. K. Harris. 1983. An improved selective medium 
for isolating Bruce/la spp from bovine milk. Proc. III Int. Sym. Vet. Lab. Diag. :577-
589. 
10. Farrell, I. D. 1974. The development of a new selective medium for the isolation of 
Bruce/la abortus from contaminated sources. Res. Vet. Sci. 16:280-286. 
11. Henry, B. S. 1933. Dissociation in the genus Bruce/la. J. Infect. Dis. 52:374-402. 
12. Keness, J., I. Friedrich, M. Banai, and S. Schonfeld. 1993. Bruce/la melitensis 
growth on Loewenstein-Jensen egg medium from a case of Bruce/la meningitis. Diagn. 
Microbiol. Infect. Dis. 17:271-273. 
13. Kuzdas, C. D., and E. V. Morse. 1953. A selective medium for the isolation of 
bruccellae from contaminated materials. J. Bacteriol. 166:502-504. 
14. Martin, J.E. J., and A. Lester. 1971. Transgrow, a medium for transport and growth 
of Neisseria gonorrhoeae and Neisseria meningitidis. HSMIIA Health Service Report 
86:30. 
15. Martin, J.E., and J. S. Lewis. 1977. Anisomycin: improved antimycotic activity in 
modified Thayer-Martin medium. Public Health Rep. 35:53-62. 
16. Martinez de Tejada, G., J. Pizarro-Cerda, E. Moreno, and I. Moriyon. 1995. The 
outer membranes of Bruce/la spp. are resistant to bactericidal cationic peptides. Infect. 
Immun. 63:3054-3061 . 
17. Martinez De Tejada, G., J. Pizzarro-Cerda, E. Moreno, and I. Moriyon. 1995. The 
outer membranes of Bruce/la spp. are resistant to bactericidal cationic peptides. Infect. 
Immun. 63:3054-3061. 
18. Miles, A. A., and S.S. Misra. 1938. The estimation of the bactericidal power of the 
blood. J. Hyg., Epidem., Microbiol. and Immunol. 38:732-749. 
32 
19. National Committee for Clinical Laboratory Standards. 1993. Methods for Dilution 
Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. 
20. National Committee for Clinical Laboratory Standards. 1993. Performance 
Standards for Antimicrobial Disk Susceptibility Tests. 
21. Olsen, S. C., N. F. Cheville, R. A. Kunkle, M. V. Palmer, and A. E. Jensen. 1997. 
Bacterial survival, lymph node pathology, and serological responses of bison (Bison 
bison) vaccinated with Bruce/la abortus strain RB51 or strain 19. J. Wildl. Dis. 33: 146-
151. 
22. Schurig, G. G., R. M. Roop Il, T. Bagchi, S. Boyle, D. Buhrman, and N. 
Sriranganathan. 1991. Biological properties of RB51; a stable rough strain of Bruce/la 
abortus. Vet. Microbiol. 28: 171-188. 
23. Skirrow, M. B. 1977. Campylobacter enteritis: a "new" disease. Br. Med. J. 2:9-11. 
24. Stevens, M. G., S. G. Hennager, S. C. Olsen, and N. F. Cheville. 1994. Serological 
responses in diagnostic tests for brucellosis in cattle vaccinated with Bruce/la abortus 19 
or RB51. J. Clin. Microbiol. 32: 1065-1066. 
Table 1. Composition of selective media 
Currently used for Brucellae selective media 
DOM EWT FAR KM MKM 
Bruce/la Ewalt's Farrell's Kuzdas & Modified 
ovis Morse Kuzdas& 
Morse 
Commercially available for Gram~~egad.;~ -1 
BGA ITM MTM SKR I 
Brilliant Improved Modified SkirroW' I 
Green Thayer- Thayer- I 
Agar' Martinb Martinb I 
BAB1 TSA2 Oxoid3 BA4 
r-------------- --- I 
BBL5 GC6 GC BA Basal Medium 
Anisomycin (µg/ml) 
Aztreonam (µg/ml) 
Bacitracin (U/ml) 
Brilliant Green (µg/ml) 
Colistin (µg/ml) 
Crystal Violet (µg/ml) 
Cycloheximide (µg/ml) 
EDT A (µg/ml) 
Ethyl violet (µg/ml) 
Lincomycin (U/ml) 
Malachite Green (µg/ml) 
Nalidixic acid (µg/ml) 
Nitrofurantion (µg/ml) 
Nystatin (U/nil) 
Polymyxin B (U/ml) 
7.5 
10 
12.5 
25 
100 
6 
100 
5 
25 
100 
5 
100 
5 
25 
1.4 
100 
6 
ISA 
7.5 
I 
I 
I 
I 30 
I 
I 
t.4 I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
1.s I 
20 
12.5 
7.5 7.5 
12.5 
2.5 
Developed media 
BRB BMG 
Bruce/la Brucellae 
abortus Malachite 
RBS! Green 
ISA ISA 
25 
100 
100 
5 
100 
100 
I • • • • I 200 
. . I I Rifampicin (µg/ml) 
Trunethopnm (µg/ml) - - - - - ' - 5 5 5 ' 5 
. I I 
Vancomycm (µg/ml) 3 - 20 - ' - 4 3 10 t 20 
'Available from BBL; •Available from Remel 
'Blood agar base; 'Tryptose agar with 5% bovine serum; 'Oxoid nutrient agar with 5% horse serum; 'Brucella agar with 5% bovine serum; 'BBL0 Brilliant Green Agar; "Reme1° GC agar base 
w 
w 
34 
Table 2. Macrodilution broth MICs for Brucellae 
RB51 RB51 544 
Working Seed Vaccine" 
Aztreonamb (µg/ml) 16 16 16 
Brilliant green° (µg/ml) 8 8 2 
Erythromycind (µg/ml) 16 16 16 
Malachite green• (µg/ml) 8 8 4 
Nalidixic Acidr (µg/ml) 16 16 16 
Polymyxin Bs (U/ml) 4 4 32 
Rifampicinh (µg/ml) 1024 1024 <I 
Trimethoprim; (µg/ml) 64 64 64 
• Colorado Serum Company, Denver, CO; • Azactanf , E.R. Squibb & Sons, Inc., Princeton, NJ~ Sigma, CI 42040~ Sigma: Sigma, CI 42000; 
'Sigma; 1Pfizer Roerig, New Yorlc, NY; "Sigma; ;Sigma 
Table 3. Growth of RB51 on Selective Media 
CFU Average 
CFU Average on TSA 
Student's T-test 
Extent of Inhibition 
Colonial Morphology 
Currently used for Brucellae selective media 
BOM EWT FAR KM MKM 
Bn1cella Ewalt's Farrell's Kuzdas & Modified 
ovis 
0 0 0 
69 127 127 
NN NA NA 
105 103 106 
NGd NG NG 
Morse 
0 
102 
NA 
104 
NG 
Kuzdas& 
Morse 
95 
100 
0.25 
NA 
Rough 
White 
'Available from BBL; •Available from Remel; 'Not applicable; "No Growth 
j Commercially available for Gram-negative I 
I BGA ITM MTM SKR I 
I Brilliant Improved Modified SkirroW' I 
I Green Thayer- Thayer- l 
l Agar' Martinb Martinb I 
I ---------
Developed media 
BRB BMG 
Bruce/la 
abortus 
RB51 
Brucellae 
Malachite 
Green 
112 0 0 63 ! 10 l 110 
194 
<0.05 
NA 
I I Rough 
l White 
I 
I 
I 
I 
I 
I 
136 
NA 
106 
NG 
124 
NA 
106 
NG 
69 
0.23 
NA 
Rough 
White 
I I 
102 
0.77 
NA 
Rough 
White 
l l l 
0.46 
NA 
Rough 
White 
w 
Vl 
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CHAPTER 3. ISOLATION OF BRUCELLA ABORTUS STRAIN RB51 FROM 
VACCINATED BISON (BISON BISON) 
A paper to be submitted to Applied and Environmental Microbiology 
Richard L. Hornsby, Allen E. Jensen, Steven C. Olsen, and Charles 0 Thoen 
Abstract 
Recovery of Bruce/la abortus RB5 l on tryptose agar with 5% bovine serum (TSA), modified 
Kuzdas and Morse (MKM), and two new selective media, B. abortus RB5 l (BRB) and 
brucellae malachite green medium (BMG), was attempted from tissues of vaccinated bison. 
The efficiency of each medium to control contaminant growth was determined. Female bison 
(n=20) were vaccinated with approximately 1.4 X 101° CFU ofRB51 at three to six months of 
age. At 14, 18, 22, 26, and 30 weeks post inoculation, four vaccinates were sacrificed and 
tissues were collected in an attempt to recover RB51 . Tissues were minced, inoculated onto 
the media, and incubated for seven days at 37°C in 5% C02. During the course ofthis study, 
RB51 was recovered from 42 samples on TSA, 19 samples on MKM, 24 samples on BRB, 
and 3 8 samples on BMG medium. RB51 was recovered on only one medium from 21 samples 
with the remaining media culture negative (9 on TSA; 3 on BRB; and 9 on BMG). Growth of 
contaminating bacteria prevented detection of RB51 from 41 samples on TSA, 24 on MKM, 
three on BRB, and 25 on BMG. Our data suggest that MKM medium is inferior to BRB and 
BMG for recovering RB51 from tissue samples and that BRB and BMG, when combined with 
TSA, enhance the ability to recover RB5 l from tissue samples. 
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Introduction 
Brucellosis, caused by Bruce/la abortus, has become endemic in free ranging bison in 
North America (2). It has been estimated that up to 20% of the female bison in Yellowstone 
National Park are infected. It has been shown that brucellae can be transmitted from bison to 
cattle ( 4). As ranged cattle encounter free ranging bison around the National Parks, there is 
potential for tramission of brucellosis from the infected bison to cattle. Historically, B. 
abortus strain 19 has been used as a vaccine to protect cattle from brucellosis. However, 
Strain 19 only protects 65 to 75 per cent of vaccinates and because strain 19 is an attenuated 
smooth organism, it can cause ambiguous results in standard serologic assays used in 
diagnosisng field cases of brucellosis. Recently, a laboratory derived mutant of B. abortus 
2308, designated RBS l (7), has been used as a vaccine against brucellosis in cattle (3) and 
bison (6). Vaccination with RB51 induces cell-mediated immune responses and provides 
protection in cattle from abortion when challenged with B. abortus 2308 (3). Also, RB5 l is 
lipopolysaccharide (LPS) 0-antigen deficient and does not invoke production of antibodies 
that cause ambiguity in serologic assays currently used for diagnosis of brucellosis in cattle 
(8). 
It has been shown that most selective media currently used for isolation ofbrucellae 
inhibit the growth ofRB51. RB51 is being used in field studies, therefore, a medium which 
will support growth of RB5 l and control contaminants found in clinical specimens is needed. 
Additionally, a medium that could be used to differentiate RB5 l from other isolates of B. 
abortus would reduce time in distinguishing the vaccine from field strains of brucellae. 
The objective in this study was to compare tryptose agar with 5% bovine serum 
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(TSA), modified Kuzdas and Morse (MKM) (1), and two recently developed selective media, 
B. abortus RB51 (BRB) and brucellae malichite green (BMG) medium for isolation ofRB51 
and inhibit growth of contaminants encountered in processing clinical veterinary samples from 
bison. 
Materials and Methods 
Vaccine. Vaccine RB51, derived from Bruce/la abortus RB51 (7) was obtained from 
Colorado Serum Company (Denver, CO). The vaccine was diluted with supplied diluent. 
The method of Miles and Mirsa (5) was used to confirm the dose given. 
Media. Composition of each medium is shown in Table 1. Three plates of TSA, two MKM, 
and one each of BRB and BMG medium were used in tissue processing. MKM and BRB 
were not used in processing two tissues and BMG was not used in processing 13 tissues. 
Bison. Twenty female bison 3-6 months of age were vaccinated subcutaneously with 
approximately 1.4 X 1010 CFU ofRB51. Four bison were necropsied at 14, 18, 22, 26, and 
30 weeks post-inoculation. 
Sample Processing. Lymph nodes processed were bronchial, hepatic, internal iliac, 
mandibular, mesenteric, parotid, popliteal, prefemoral, retropharyngeal, superior cervical, and 
supramammary. Other tissues included bone marrow, cerebral spinal fluid, ileum, kidney, 
liver, mammary gland, ovary, spleen, synovial fluid, uterus and feces. Tissues were surface 
disinfected, minced with sterile scissors and inoculated onto TSA (n = 3), MKM (n = 2), BRB 
(n = 1), and BMG (n = 1) plates. Plates were incubated at 37°C in 5% COz, observed at 24 h 
for contaminants and at seven days for grow of RB5 l and contaminants. RB5 l was identified 
by growth characteristics, colonial morphology, and the acriflavine test (1). 
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Results 
B. abortus RB51 was isolated from 42 of 436 samples (9.6%), and 41 samples were 
contaminated (9.4%) on TSA (Table 2). RB51 was isolated from 19of434 samples (4.3%) 
and 24 samples were contaminated (5.5%) on MKM. RB51 was isolated from 24 of 434 
samples (5 .5%), and 3 samples were contaminated (0.07%) on BRB. RB51 was isolated from 
38 of 423 samples (9.0%), and 25 samples were contaminated (5 .9%) on BMG. In 21 
instances, RB51 was isolated on only one of the four media, while the other media were either 
contaminated or culture negative. Of these 21 instances, nine were on TSA, three were on 
BRB, and nine were on BMG. RB51 was not solely isolated on MKM. No RB51 was 
isolated after 26 weeks post vaccination. 
Discussion 
This study has shown that RB51 can persist up to 26 weeks post-vaccination in young bison. 
RB51 is being used to vaccinate free ranging bison in and around the national parks; therefore 
it is essential that a selective media that supports the growth of RB51 be available. Ideally, 
the media would support growth of RB51 as well as TSA and inhibit all contaminants 
commonly encountered in processing of clinical veterinary samples. MKM was the least 
successful in recovering RB51 . While RB51 was recovered fewer times on BRB than TSA or 
BMG, there were only three contaminated plates. RBS 1 was recovered from 9% of the 
samples on BMG and 9.6% on TSA. However, 9.4% of the samples on TSA were 
contaminated and only 5.9% on BMG. This study shows that BRB and BMG, when used 
with TSA, enhances the recovery B. abortus RB51 when processing bison tissues. 
40 
References 
1. Alton, G. G., L. M. Jones, RD. Angus, and J.M. Verger (Eds.). 1988. Techniques 
for the brucellosis laboratory. Institut National de la Recherche Agronomique, Paris. 
2. Baskin, Y. 1997. Study shows one-fifth of female bison infected. Science 276:1786. 
3. Cheville, N. F., M. G. Stevens, A. E. Jensen, F. M. Tatum, and S. M. Halling. 1993 . 
Immune responses and protection against infection and abortion in cattle experimentally 
vaccinated with mutant strains of Bruce/la abortus. Am. J. Vet. Res. 54: 1591-1597. 
4. Davis, D. S., J. W. Templeton, T. A. Ficht, J. D. Williams, J. D. Kopec, and L. G. 
Adams. 1990. Bruce/la abortus in captive bison. I. serology, bacteriology, pathogenesis, 
and transmission to cattle. J. Wildl. Dis. 26:360-371. 
5. Miles, A. A., and S. S. Misra. 1938. The estimation of the bactericidal power of the 
blood. J. Hyg., Epidemiol. , Microbiol. and Immunol. 38:732-749. 
6. Olsen, S. C., N. F. Cheville, RA. Kunkle, M. V. Palmer, and A. E. Jensen. 1997. 
Bacterial survival, lymph node pathology, and serological responses of bison (Bison 
bison) vaccinated with Bruce/la abortus strain RB5 l or strain 19. J. Wildl. Dis. 33: 146-
151. 
7. Schurig, G. G., R M. Roop II, T. Bagchi, S. Boyle, D. Buhrman, and N. 
Sriranganathan. 1991. Biological properties ofRB5 l ; a stable rough strain of Bruce/la 
abortus. Vet. Microbiol. 28:171-188 . 
8. Stevens, M. G., S. G. Hennager, S. C. Olsen, and N. F. Cheville. 1994. Serological 
responses in diagnostic tests for brucellosis in cattle vaccinated with Bruce/la abortus 19 
or RB51. J. Clin. Microbial. 32: 1065-1066. 
41 
Table 1. Composition of Media 
TSA MKM BRB BMG 
Basal Medium TSA TSA TSA TSA 
Aztreonam (µg/ml) 5 
Bacitracin (µg/ml) 25 25 
Cycloheximide (µg/ml) 100 100 100 
EDTA (µg/ml) 100 
Ethyl Violet (µg/ml) 1.4 
Malachite Green (µg/ml) 1 
Nystatin (units/ml) 100 
Polymyxin B (units/ml) 6 
Rifampin (µg/ml) 200 
Trimethoprim (µg/ml) 5 
Vancomycin (µg/ml) 20 
Table 2. Evaluation of selective media. 
TSA MKM BRB BMG 
Total Isolations 42 19 24 38 
Sole Isolation 9 0 3 9 
Medium 
Total 41 24 3 25 
Contaminated 
Total Samples 436 434 434 423 
% Positive of Total 9.6% 4.3% 5.5% 9.0% 
Samples 
% Contaminated of 9.4% 5.5% 0.07% 5.9% 
Total Samples 
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CHAPTER 4. GENERAL CONCLUSIONS 
General Discussion 
Bruce/la abortus RB51 is being used to vaccinate cattle (2) and free ranging bison (9, 10) 
in the United States. In order to determine if future abortions in cattle and bison vaccinates are 
the result of the vaccine or its failure to protect, it is essential that a selective media that supports 
the growth ofRB5 l be available. Ideally, the media would support growth of RB5 l and inhibit 
contaminants commonly encountered in processing of clinical veterinary samples. This study has 
shown that Bruce/la ovis selective medium (1) Ewalt's (3), Farrell' s (4), and Kuzdas and Morse 
medium ( 6) inhibit the growth of RB 51 . The inhibitory agent in these media is polymyxin B or 
polymyxin E. If the level of polymyxin B or E is reduced in these media, there will be problems 
with contamination. Therefore, another agent that would inhibit Gram-negative bacteria but not 
brucellae, especially RB5 l , was needed. 
This study showed there were six possible agents, aztreonam, EDT A, erythromycin, 
malachite green, nalidixic acid, and rifampicin. The resistance ofRB51 to EDTA may be due to 
the unusual lipid composition of Brucel/a LPS (8). B. abortus LPS has been shown to contain 
2. 7 times less 2-keto-3-deoxyoctonate (KDO) than E. coli 0128 :B12 LP S (7) . Since the KDO 
residues ofLPS are responsible for the binding of divalent cations, this may be the mechanism of 
resistance. As mentioned previously brucellae are also resistant to polycationic peptides such as 
magainin and cecropin (5). The ability of RB5 l to grow on medium containing malachite green 
may demonstrate a modification in the omp 2 gene. Its polymorphism and ability to modify its 
product post-translationally is considered responsible for dye sensitivity in Brucella. 
Rifampicin and EDT A were incorporated with Gram-positive and fungal inhibitors and designated 
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Bruce/la RB medium (BRB). BRB supported the growth of RB51 and was effective in recovery 
of RB51 from cattle and bison tissues while inhibiting growth of contaminants remarkably. 
Malachite green, aztreonam and EDTA were incorporated with Gram-positive and fungal 
inhibitors and designated Brucella Malachite green medium (BMG). BMG was effective in 
recovery ofRB51 from cattle and bison tissues and B. abortus 2308 from cattle tissues while 
inhibiting growth of contaminants. This study shows that when processing bison tissues for 
recovery of B. abortus RB5 l, BRB and BMG used in conjunction with TSA will achieve the best 
results. 
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APPENDIX 
Table 1. Growth of B. abortus RB51 on Basal Media 
Plate Plate Plate Plate Plate 
1 2 3 4 5 
Tryptose Agar 
RB51 58 71 35 61 53 
Brucella Agar 
RB51 51 51 47 50 35 
Mueller-Hinton Agar 
RB51 55 35 50 59 30 
Trypticase Soy Agar 
RB51 37 55 17 49 50 
Plate Plate Plate 
6 7 8 
56 36 54 
36 69 62 
34 57 29 
56 54 31 
Plate 
9 
43 
57 
32 
65 
Plate 
10 
43 
50 
51 
56 
Ave 
51 
51 
43 
47 
~ 
O'\ 
Table 2. Disk diffusion results 
BruceUa BructUa Brucdla BructUa BruetUa BruetUa BruuctUa BruceUa BruetUa BruetUa 
abortus abortus abortus 2JOs3 abortusst<r abortus 544' can It mellten1lsl6 ntotlllftlt ovls 
"''' RBS11 RBS11 RM-666" M' SKJJ' 6J/29o' UJo•• 
Azlocillin (7 5 mcg) s s s s s s s s s s 
Carbenicillin ( 100 mcg) s s s s s s s s s s 
Mezlocillin (75 mcg) s s s s s s s s s s 
Penicillin G (10 units) s s s s s s I s s s 
Piperacillin (100 mcg) s s s s s s s s s s 
Ticarcillin/ Clavulanic acid s s s s s s s s s s 
(75/10 mcg) 
Cefixime (5 mcg) s s s s s s s s s 
Cefoperazone (7 5 mcg) s s s s s s s s s s 
Cefotaxime (30 mcg) s s s s s s s s s s 
Ceftizoxime (30 mcg) s s s s s s s s s s 
Imipenim (10 mcg) s s s s s s s s s s 
Aztreonam (30mcg) R R R R R R R R R R 
Vancomycin (30 mcg) R R R R R R R R R R ~ 
-....) 
Kanamycin (30 mcg)S s s s s s s s s s s 
Streptomycin (10 mcg) s s s s s s s s s s 
Tobramycin (10 mcg) s s s s s s s s s s 
Azithromycin (15 mcg) s s s s R s s s s s 
Clarithromycin (15 mcg) I R s s R s s s s s 
Erythromycin ( 15 mcg) R R s s s s s s s s 
Dicloxacillin (l mcg) s s s s s s s s s s 
Minocycline (30 mcg) s s s s s s s s s 
1 BruceUa aborlus RB51 ARS Master Seed; 2BruceUa aborlus RB51 Colorado Serum Company Vaccine; 'BruceUa aborl11S 2308 ·Parental strain ofRB51; • Brucella aborlus vaccine strain 19; 'BrnceUa obortus biovar I type strain (ATCC" # 23448); 
6 Brucella canls RM-666 (ATCC" #23365); 1 Bruce/la mtlilensls 16M (ATCC., #23456); 8BruceUo neotomae 5K33 (ATCC., #23459); 'Bruce/la ovls 631290 (ATCC., #25840); 10Brucella suls 1330 (ATCC" # 23444) 
Table 2. (continued} 
BrucellJJ BrucellJJ BrucellJJ BrucellJJ BructllJJ BructJla BruuctJJa BrucellJJ BructllJJ BrucellJJ 
abortus abortus abortus 2308' abortusSl9' abortus s••' canls mellten1lrl 6 ntotamlt om tuls 
RBSl1 RBSl2 RM-'66' M' SKJJ' 631190" UJ010 
Tetracycline (30 mcg) s s s s s s s s s s 
Cinoxacin (100 mcg) s s I s s s I I s s 
Ciprofloxacin (5 mcg) s s s s s s s s s s 
Enoxacin (I 0 mcg) s s s s s s s s s s 
Lomefloxacin (I 0 mcg) s s s s s s s s s s 
Ofloxacin (5 mcg) s s s s s s s s s s 
Bacitracin (10 units) R R R R R R R R R R 
Cholramphenicol (30 mcg) s s s s s s s s s s 
Clindamycin (2 mcg) R R R R R R R s R R 
Colistin ( 10 mcg) s s s I R R R s R R 
Colistin (30 mcg) s s s s s s s s s s 
Lincomycin (2 mcg) R R R R R R R R R R 
Nalidixic Acid (30mcg) R I R R I I R R R I ~ 00 
Nitrofurantoin (300mcg) s s s s s I s s s s 
Novobiocin (30 mcg) I I s s s s s s s s 
Nystatin (100 units) R R R R R R R R R R 
Polymyxin B (300 units) s s s s s I I s s s 
Rifampin (5 mcg) R R s s s s s s s s 
Trimethoprim (5 mcg) R R R R R R R R R R 
Trimethoprim/Sulfamethoxazole I s s s I s R s R s 
(1.25/23.75 mcg) 
Triple Sulfa (300 mcg) I s s s R s I s R s 
Table 3. Disk diffusion results 
14671 13032 14923 12384 11375 14796 14817 14838 
Azlocillin (75 mcg) s s s s s s s s 
Carbenicillin (100 mcg) s s s s ND s s s 
Mezlocillin (75 mcg) s s s s s s s s 
Penicillin G (10 units) s s s s s R s R 
Piperacillin (100 mcg) s s s s s s s s 
Ticarcillin/ Clavulanic acid (75/10 mcg) s s s s s s s s 
Cefixime (5 mcg) s s s s s s R R 
Cefoperazone (7 5 mcg) s s s s s s s s 
Cefotaxime (30 mcg) s s s s s R R I 
Ceftizoxime (30 mcg) s s s s s s s R 
Imipenim (10 mcg) s s s s s s s s 
Aztreonam (30mcg) R R R R R s R s 
Vancomycin (30 mcg) R R R R R R R R 
Kanamycin (30 mcg)S s s s s s I s R .i:.. 'Cl 
Streptomycin (10 mcg) s s s s s I I R 
Tobramycin (IO mcg) s s s s s ND ND ND 
Azithromycin (15 mcg) s s s R R I s s 
Clarithromycin ( 15 mcg) s s s R R R s R 
Erythromycin (15 mcg) R R I R R R s R 
Dicloxacillin ( 1 mcg) s s s s s s s R 
Minocycline (30 mcg) s s s s s I s R 
1 Bruce/la abortus RB5 l passed 202 times; 2Brucel/a abortus RB5 l isolated from cow blood; 3 Bnice/la abortus RB5 l isolated from Bison vaccinated with RB5 l; 4Bnicella abortus I isolated from 
Elk; 'Bruce/la abortus I isolated from Bison; 6 Escherichia coli (ATCC® 25922); 7 Staphylococus aureus-aureus (ATCC® 25923); 8 Pseudomonas aeruginosa (ATCC® 27853) 
Table 3. {continued} 
14671 13031 14923 12384 11375 14796 1481' 1483 
Tetracycline (30 mcg) s s s s s s s R 
Cinoxacin (100 mcg) s s s s s s R R 
Ciprofloxacin (5 mcg) s s s s s s s s 
Enoxacin (IO mcg) s s s s s s s s 
Lomefloxacin (IO mcg) s s s s s s s I 
Ofloxacin (5 mcg) s s s s s s s s 
Bacitracin (IO units) R R R R R R s R 
Cholramphenicol (30 mcg) s s s s s s s R 
Clindamycin (2 mcg) R R R R R R s R 
Colistin (lO mcg) s s R R R s R R 
Colistin (30 mcg) s s s s s s s s 
Lincomycin (2 mcg) R R R R R R s R 
Nalidixic Acid (30mcg) R R R I I s R R 
Nitrofurantoin (300mcg) s s s s s s s R Vo 0 
Novobiocin (30 mcg) I I I s s R s R 
Nystatin (IOO units) R R R R R R R R 
Polymyxin B (300 units) s s s s s s I s 
Rifampin (5 mcg) R R R s s R s R 
Trimethoprim (5 mcg) R R R R R s s R 
Trimethoprim/Sulfamethoxazole (1.25/23.75 mcg) I s I s s s s R 
Triple Sulfa (300 mcg) R R R R R R R R 
Table 4. Broth Dilution MICs for Aztreonama 
~g/ml RB51 1 13032 14673 5444 2308~ 19(> 1479' 1480~ 1481 
.125 + + + + + + + + + 
.25 + + + + + + - + + 
.5 + + + + + + - + + 
+ + + + + + - + + 
2 + + + + + + - + + 
4 + + + + + + - + + 
8 + + + + + + - - + 
16 + + + - - + - - + 
32 - - - - - - - - + 
64 
128 
256 
512 
'Azactam'". E.R. Squibb&. Sons, Inc., Princeton, NJ; 1BnJctUa ahortus RBS! Colorado Serum Company Vaccine; 2BnJctUa ahortus RBS! isolated from cow blood; 'BnJctlla ahortus RBS! passed 202 times; 4BnJctUa ahortus biovar l type strain (ATcc• # 
23448); 'BnJctUa ahortus 2308 ·Parental strain of RBS I; 'Broce/la ahortus vaccine strain 19; 'Escherichia coli (ATCC9 2S922); 'Escherichia coli (ATCC'" 3S218); 9Staph~ococus aureus·aurtus (ATCC'" 2S923) 
Vl 
...... 
Table 5. Broth Dilution MICs for Brilliant Green 
µg/ml RB51 - Working Seed RB51 - Vaccine 
TS81 BS81 MYHS TSB BSD MYHS TSB 
) 
1 + + + + + + 
2 + + + + + + 
4 + + + + + + 
8 
16 
32 
64 
128 
256 
512 
1024 
544 
BSD MYHS TSB 
+ 
1Tryptose broth with 5% bovine serum; 'Brucella broth with 5~. bovine serum; 'Mueller-Hinton broth with 5% bovine serum and 0.5% 1""'t extract 
2308 
BSD MYHS TSB 
+ + 
+ 
19 
BSD 
+ 
+ 
MYHS 
+ 
+ 
VI 
N 
Table 6. Growth of Brucellae and Control organisms on Media Containing D!es and Eryrithrotol 
Basic fuchsin i-eryrithrotol Safranin 0 Thionin Thi on in Thionin 
20 !!&:'.ml I mg/ml 100 !!&:'.ml 2 µg/ml 20 !!&:'.ml 40 !!&:'.ml 
RB51 1 A' + + + + 
Bb + + + + 
C' + + + + 
od 
13032 A + + + + 
B + + + + 
c + + + + 
D 
14671 A + + + + 
B + + + + 
c + + + + 
D 
5444 A + + + + 
B + + + + 
c + + + + 
D 
2308s A + + + + 
B + + + + 
c + + + + 
D 
196 A + + + 
B 
- -
+ + 
c 
-
+ + 
-
D 
- -
+ 
14797 A + + + + + + 
B + + + + + + 
c + + + + + + 
D + + 
14808 A + + + + + + 
B + + + + + + 
c + + + + + + 
D + - - + 
1481 9 A + + + + + 
B + + + + + 
c 
-
+ - + + + 
D 
-
+ 
- - + 
'illOZllium = 5.0 X 10' CFU;' inoculum = 5.0 X 101 CFU;' inoculum = 5.0 X 102 CFU;' inoculum = 5.0 X 101 CFU; 'Broce/la abortu• RB51 Colorado Serum Company Vaccine; 2Broctlla abortu• RB51 isolated from cow blood; 'Broce/la aborh" RB51 passed 
202 times; 'BniceUa abor/11• biovar 1 type strain (ATcc• # 23448); ' Broctlla abortu• 2308 - Parental strain ofRB51; 6Brt1ctUa abortu• vaccine strain 19; 1E>eherichia coli (ATCC" 25922); 'E•chtrichla coli (ATCC9 35218); 9Staphylococu• aureu•-aurtu• 
(ATCC" 25923) 
Vo 
w 
Table 7. Com[!osition of Ex[!erimental Selective Media 
Junl Jun2 Jun3 Jun4 Jull Jul2 Jul3 Jul4 Jul5 Jul6 Jul7 
Basal Medium TSA TSA TSA TSA TSA1 TSA TSA TSA TSA TSA TSA 
Aztreonam (µg/ml) - - - - - - - 5 5 5 
Brilliant Green (µg/ml) - - - 5 - 1 - - 1 - 1 
Cycloheximide (µg/ml) 100 100 100 100 50 50 50 50 50 50 50 
EDT A (µg/ml) - - - - 100 100 100 100 100 100 100 
Ethyl Violet (~tg/ml) 1.4 
Malachite Green - - 1 - 1 - - 1 - - 1 
(µg/ml) 
Vo 
~ 
Nystatin (units/ml) - 100 
Polymyxin B (units/ml) IO 
-
2.5 2.5 2.5 2.5 2.5 
Rifampin (µg/ml) - 200 - - - - 200 - - 200 200 
Trimethoprim (µg/ml) - - - - 5 5 5 5 5 5 
Vancomycin (µg/ml) 20 25 25 25 25 25 25 25 25 25 
Table 8. Average CFU/ml of brucellae on Selective Media 
TSA Jull Jul2 
Brucella abortus RB51 
Average CFU/m11 43 28 33 
Plate 1 36 23 18 
Plate 2 15 4 12 
Plate 3 13 15 20 
Brucella abortus 544 
Average CFU/ml1 104 32 35 
Plate 1 88 20 15 
Plate 2 48 15 20 
Plate 3 20 13 18 
Brucella abortus 19 
Average CFU/m11 100 129 99 
Plate 1 65 53 58 
Plate 2 60 64 58 
Plate 3 25 77 32 
105. ml plated 
Jul3 
18 
10 
12 
5 
0 
0 
0 
0 
0 
0 
0 
0 
Jul4 
45 
25 
24 
18 
33 
14 
20 
15 
104 
57 
45 
54 
Jul5 
44 
8 
44 
14 
93 
57 
58 
25 
96 
70 
61 
13 
Jul6 
37 
10 
23 
23 
0 
0 
0 
0 
0 
0 
0 
0 
Jul7 
33 
11 
20 
18 
0 
0 
0 
0 
0 
0 
0 
0 
VI 
VI 
Table 9. Com~osition of Ex~erimental Selective Media 
RBl RB2 RB3 RBS RB6 RB7 MSl MSlO MSll MS12 MS13 
Basal Medium TSA TSA TSA TSA TSA1 TSA TSA TSA TSA TSA TSA 
Aztreonam (µg/ml) - - - - - - - - 8 8 8 
Bacitracin (µg/ml) 25 25 25 25 25 25 
Crystal Violet (µg/ml) - - - - - - - l - 1 
Cycloheximide (µg/ml) 100 100 100 100 100 100 
EDT A (µg/ml) - - - - - - 100 100 100 100 100 
Fluconazole - - - - - - 25 25 25 25 25 
Furazolidone (µg/ml) - - - - - 10 
Vo 
0\ 
Malachite Green (µg/ml) - - - - - - 1 I 1 1 I 
Nystatin (units/ml) 100 100 100 100 100 100 
Polymyxin B (units/ml) - - 0.5 
Rifampin (µg/ml) - 200 100 200 200 
Trimethoprim (µg/ml) - - - - 5 - - - - - 5 
Trimethoprim/ 0.5/10 
sulfamethoxazole (µg/ml) 
Vancomycin (µg/ml) 20 20 20 20 20 20 25 
Table 10. Average CFU/ml of brucellae on Selective Media 
TSA RBl RB2 RB3 RBS RB6 RB7 MSlO MSll MS12 MS13 
Bntcella abortus RB5 l 
Average CFU/ml1 43 28 33 18 45 44 37 42 44 42 37 
Plate I 36 23 18 10 25 8 10 37 38 45 39 
Plate 2 15 4 12 12 24 44 43 47 46 40 35 
Plate 3 13 15 20 5 18 14 23 42 48 41 37 
Bmcella abortus 544 
Average CFU/ml1 104 32 35 0 0 0 0 ND ND ND ND 
Plate 1 88 20 15 0 0 0 0 
Plate 2 48 15 20 0 0 0 0 
Plate 3 20 13 18 0 0 0 0 
Bn1cel/a abortus 19 
Average CFU/ml1 100 129 99 0 104 0 0 ND ND ND ND 
Plate 1 65 53 58 0 57 0 0 
Plate 2 60 64 58 0 45 61 0 
Plate 3 25 77 32 0 54 13 0 
105. ml plated 
Vl 
-...J 
Table 11. Results of Fort Niabrara bison tissues on TSA and selective media 
Bison I 001 002 
T K R M 
- - -
ND 
- - - -
- - -
ND 
- - - -
+ - - -
- - - -
- - - -
- - - -
- - -
ND 
+ - - ND 
+ - - -
- - - -
- - - -
- - - -
c c c c 
- - - -
- - - -
- - - -
- - - -
- - -
ND 
- - - -
- - - -
ND ND ND ND 
1 T/K/R/M = TSNModified Kuzdas and Morse medium/Rifampin medium/Malachite Green medium 
( +) =Bruce Ila abortus RBS I; (-) = negative; C = contaminated; ND = not done 
003 
T K R 
- - -
- - -
- - -
+ + + 
- - -
+ - -
+ + + 
- - -
+ + + 
+ + + 
+ + -
- - + 
- - -
ND ND ND 
c c -
- - -
- - -
- - -
- - -
- - -
- - -
- - -
ND ND ND 
M 
-
-
-
+ 
-
+ 
+ 
+ 
ND 
ND 
+ 
-
-
ND 
c 
-
-
-
-
ND 
-
-
ND 
004 
T K R M 
- - -
ND 
- - - -
- - - -
- - - -
- + + + 
+ - + + 
- - - -
+ - - + 
+ + + ND 
+ + - ND 
c - - c 
+ - - + 
- - - -
ND ND ND ND 
c c 
-
c 
- - - -
- - - -
- - - -
- - - -
- - - -
ND ND ND ND 
- - - -
ND ND ND ND 
005 
T K R 
- - -
- - -
- - -
+ - + 
c - -
+ - + 
+ + + 
- - -
+ + + 
+ - -
- - -
+ - -
ND ND ND 
- - -
c c c 
- - -
- - -
- - -
- - -
- - -
- - -
ND ND ND 
ND ND ND 
M 
-
-
-
+ 
-
-
+ 
-
+ 
-
+ 
-
ND 
-
c 
-
-
-
-
-
-
ND 
ND 
Vl 
00 
Bison 006 007 
T K R M T K R M 
Bronchial LN + + + + + - - -
Hepatic LN 
- - - - - - - -
Int. Iliac LN - - - - - - - -
Mandibular LN c + + + - - - + 
Mesenteric LN - - - - - - - -
Parotid LN c - + - + - - + 
Popliteal LN c + - + - - + + 
Prefemoral LN c - - - - - - + 
Prescapular LN -Left + + + + + + + + 
Prescapular LN -Right + - + + + + + + 
Retropharyngeal LN c - - + c - - c 
Supramammary LN + - + + + - + + 
Bone Marrow c - - - - - - -
CSF - - - - - - - -
Ileum c c 
-
c c c - c 
Kidney - - - - - - - -
Liver - - - - - - - -
Mammary Gland 
- - - - - - - -
Ovary - - - - - - - -
Spleen 
- - - - - - - -
Synovial Fluid 
- - - - -
- - -
Uterus ND ND ND ND ND ND ND ND 
Feces ND ND ND ND ND ND ND ND 
TIKIRJM = TSA/Modified Kuzdas and Morse medium/Rifampin medium/Malachite Green medium 
(+) =Bruce/la abortus RB51; (-) = negative; C = contaminated; ND = not done 
008 009 
T K R M T K 
- - - -
c 
-
- - - - - -
- - - - - -
+ - - + - -
- - - - - -
+ - - + - -
+ - - + - -
- - - - - -
+ + - + - -
+ - - + - -
c - - c - -
- - - - - -
- - - - - -
ND ND ND ND 
- -
c c - c c c 
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
ND ND ND ND c -
c c 
-
c c c 
R M T 
- - -
- - -
- - -
- - -
- - -
- - -
- - -
- - -
- - + 
- - -
- - -
- - -
- - -
- -
ND 
- c c 
- - -
- - -
- - -
- - -
- - -
- - -
- - c 
- c c 
010 
K R 
- -
- -
- -
- -
- -
- -
- -
- -
ND ND 
ND ND 
- -
- -
- -
ND ND 
c -
- -
- -
- -
- -
- -
- -
- -
c c 
M 
-
-
-
-
-
-
-
-
-
+ 
-
-
-
ND 
c 
-
-
-
-
-
-
-
c 
Vl 
\0 
Bison I 011 012 
T K R M T K R M 
Bronchial LN 
Hepatic LN - - - - - - - -
Int. Iliac LN - - - - - - - -
Mandibular LN - - - - - - - -
Mesenteric LN - - - - - - - -
ParotidLN - - - - - - - -
Popliteal LN 
- - - - - - -
Prefemoral LN - - - - - - - -
Prescapular LN -Left - - - - - - - -
Prescapular LN -Right 
- - - - - - - -
Retropharyngeal LN c - - - - - - -
Supramammary LN - - - - - - - -
Bone Marrow 
- - - - - - - -
CSF - - - - - - - -
Ileum c c 
- -
c c - -
Kidney 
- - - - - - - -
Liver - - - - - - - -
Mammary Gland c - - - - - - -
Ovary ND ND ND ND c 
- - -
Spleen - - - - - - - -
Synovial Fluid 
- - - - - - - -
Uterus c - - - c - - -
Feces c c - c c c - c 
1 TIKIR/M = TSNModified Kuzdas and Morse medium!Rifampin medium/Malachite Green medium 
( +) = Bruce I/a abortus RBS I; (-) = negative; C = contaminated; ND = not done 
T 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
c 
-
-
-
-
-
-
-
c 
013 014 
K R M T K R 
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - + - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
c - c c c -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
- - - - - -
c 
- c c c -
M T K 
- - -
- - -
- - -
- + -
- - -
- - -
+ + -
- - -
- - -
- - -
- c -
- - -
- - -
- - -
c c c 
- - -
- - -
- c -
- - -
- - -
- - -
- - -
c c c 
015 
R 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
M 
-
-
-
+ 
-
-
+ 
-
-
-
+ 
-
-
-
c 
-
-
-
-
-
-
-
c 
0\ 
0 
Bison I 016 017 
T K R M T K R M 
Bronchial LN - - - - - - - -
Hepatic LN 
- - - - - - - -
Int. Iliac LN - - - - - - - -
Mandibular LN - - - - - - - -
Mesenteric LN - - - - - - - -
Parotid LN - - - - - - - -
Popliteal LN 
- - - - - - - -
Prefemoral LN - - - - - - - -
Prescapular LN -Left - - - - - - - -
Prescapular LN -Right - - - - - - - -
Retropharyngeal LN - - - - c - - -
Supramammary LN 
- - - - c - - -
Bone Marrow - - - - - - - -
CSF c - - c c - - -
Ileum c c c c c - - -
Kidney - - - - - - - -
Liver - - - - - - - -
Mammary Gland 
- - - - - - - -
Ovary c - - - - - - -
Spleen 
- - - - - - - -
Synovial Fluid 
- - - - - - - -
Uterus c - - c c - - -
Feces c c c c ND ND ND ND 
T/K/R/M = TSNModified Kuzdas and Morse medium/Rifampin medium/Malachite Green medium 
(+) =Bruce/la abortus RBSl; (·) = negative; C =contaminated; ND = not done 
018 019 020 
T K R M T K R M T K R M 
- - - - - - - - - - - -
c 
- - - - - - - - - - -
- - - - - - - - - - - -
- - - - - - - - - - - -
- - - - - - - - - - - -
- - - - - - - - - - - -
- - - - - - - - - - - -
c 
- - - - - - - - - - -
- - - - - - - - - - - -
- - - - - - - - - - - -
- - - - - - - - - - - -
°' 
-c - - - - - - - - - - -
- - - - - - - - - - - -
- - - - - - - - - - - -
c - - - c - - - c - - -
- - - - - - - - - - - -
- - - - - - - - - - - -
- -
- - c - - - c - - -
- - - - - - - - - - - -
- - - - - - - - - - - -
- - - - - - - - - - - -
ND ND ND ND 
- - - - ND ND ND ND 
ND ND ND ND ND ND ND ND ND ND ND ND 
Table 12. Results of cattle tissues on TSA and selective media 
Cow I 228 229 231 
T K R M T K R M T K R M 
Blood - - - - - - - - - - - -
Vaginal Swab c - - - + + + + c - - -
Parotid LN 
- - - -
ND ND ND ND - - - -
Prescapular LN - - - - ND ND ND ND - - - -
Supramammary LN - - - - ND ND ND ND - - - -
Hepatic LN 
- - - -
ND ND ND ND 
- - - -
Int. Iliac LN - - - - ND ND ND ND - - - -
Mandibular LN - - - - ND ND ND ND - - - -
Bronchial LN 
- - - -
ND ND ND ND - - - -
Retropharyngeal LN c 
- - -
ND ND ND ND 
- - - -
Mammary Gland A c - - - ND ND ND ND - - - -
Mammary Gland 8 c - - - ND ND ND ND c - - -
Mammary Gland C c - - - ND ND ND ND - - - -
Mammary Gland D c 
- - -
ND ND ND ND c - - -
Placenta c 
- - -
ND ND .ND ND c - - -
Placetome - - - - ND ND ND ND c - - -
Uterus ND ND ND ND ND ND ND ND ND ND ND ND 
Colostrum Cream LF - - - - - - - - c - - -
Colostrum Sediment LF ND ND ND ND - - - - ND ND ND ND 
Colostrum Cream LR c - - - c - - - - - - -
Colostrum Sediment LR ND ND ND ND c + - + ND ND ND ND 
Colostrum Cream RF 
- - - - - + - - - - - -
Colostrum Sediment RF ND ND ND ND 
- - - -
ND ND ND ND 
Colostrum Cream RR - - - - c + - + - - - -
Colostrum Sediment RR ND ND ND ND c + - + ND ND ND ND 
Calf 
Blood 
- - - - - - - - - - - -
Rectal Swab c 
- - -
c + + + - - - -
Abomasol Fluid - - - - ND ND ND ND - - - -
Liver 
- - - - c - - - - - - -
Lung 
- - - - c + - - - - - -
Spleen - - - - - - - - - - - -
1 T/KJR/M = TSNModified Kuzdas and Morse medium/Rifampin medium/Malachite Green medium 
(+) = Bruce/la abortus 2308; (-)=negative; C =contaminated; ND = not done 
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T K R M 
- -
ND ND 
c 
-
ND ND 
- -
ND ND 
- - ND ND 
- -
ND ND 
- -
ND ND 
- - ND ND 
+ + ND ND 
- -
ND ND 
- -
ND ND 
c 
-
ND ND 
c - ND ND 
c 
-
ND ND 
c - ND ND 
c - ND ND 
c - ND ND 
ND ND ND ND 
- -
ND ND 
ND ND ND ND 
- -
ND ND 
ND ND ND ND 
c - ND ND 
ND ND ND ND 
- - ND ND 
ND ND ND ND 
- -
ND ND 
- - ND ND 
- -
ND ND 
- -
ND ND 
- -
ND ND 
- - ND ND 
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T K R 
- - -
c 
- -
- - -
- - -
- - -
- - -
- - -
- - -
- - -
c + -
c - -
c 
- -
c - -
c 
- -
- - -
- - -
ND ND ND 
c 
- -
ND ND ND 
c - -
ND ND ND 
- - -
ND ND ND 
c - -
ND ND ND 
- - -
- - -
c 
- -
- - -
- - -
- - -
M 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
ND 
-
ND 
-
ND 
-
ND 
-
ND 
-
-
-
-
-
-
0\ 
N 
' 
Cow I 236 237 239 
T K R M T K R M T K R M 
Blood 
- - - - - - - - - -
ND ND 
Vaginal Swab c - - - c - - - c - ND ND 
Parotid LN + - - - + + - - + - ND ND 
Prescapular LN - - - - - - - - - - ND ND 
Supramammary LN - - - - - - - - - - ND ND 
Hepatic LN - - - - - - - - - - ND ND 
Int. Iliac LN - - - - - - - - - - ND ND 
Mandibular LN - + - + - - - - + + ND ND 
Bronchial LN - - - - - - - - + + ND ND 
Retropharyngeal LN - - - - - - - + + ND ND 
Mammary Gland A c 
- - - - - - - - -
ND ND 
Mammary Gland B c - - - - - - - - - ND ND 
Mammary Gland C c - c - - - - - - - ND ND 
Mammary Gland D c - c - - - - - c - ND ND 
Placenta c - c - ND ND ND ND c - ND ND 
Placetome - - - - ND ND ND ND - - ND ND 
Uterus ND ND ND ND - - - - ND ND ND ND 
Colostrum Cream LF - - - - - - - - c - ND ND 
Colostrum Sediment LF ND ND ND ND ND ND ND ND ND ND ND ND 
Colostrum Cream LR 
- - - - - - - -
ND ND ND ND 
Colostrum Sediment LR ND ND ND ND ND ND ND ND ND ND ND ND 
Colostrum Cream RF c - - c - - - - - - ND ND 
Colostrum Sediment RF ND ND ND ND ND ND ND ND ND ND ND ND 
Colostrum Cream RR - - - - - - - - - - ND ND 
Colostrum Sediment RR ND ND ND ND ND ND ND ND ND ND ND ND 
Calf 
Blood 
- - - -
ND ND ND ND - - ND ND 
Rectal Swab - - - - ND ND ND ND - - ND ND 
Abomasol Fluid - - - - ND ND ND ND c - ND ND 
Liver - - - - ND ND ND ND - - ND ND 
Lung - - - - ND ND ND ND - - ND ND 
Spleen - - - - ND ND ND ND - - ND ND 
T/K/R/M = TSA/Modified Kuzdas and Morse medium/Rifampin medium/Malachite Green medium 
(+) = Bruce/la abortus 2308; (-)=negative; C =contaminated; ND= not done 
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T K R M T 
- - - - -
- - - - + 
- -
- -
ND 
- - - -
ND 
- - - - c 
- - - -
ND 
- - - -
ND 
- - - - ND 
- - - -
ND 
c - c - ND 
- - - -
ND 
- - - -
ND 
- - - -
ND 
- - - -
ND 
- - - - c 
- - - - c 
ND ND ND ND ND 
- - - - c 
ND ND ND ND c 
- - - - c 
ND ND ND ND c 
- - - - c 
ND ND ND ND c 
- - - - c 
ND ND ND ND c 
- - - - -
- - - - c 
- - - -
ND 
- - - - c 
c - - - c 
c - - - -
241 
K R 
- -
+ c 
ND ND 
ND ND 
+ 
-
ND ND 
ND ND 
ND ND 
ND ND 
ND ND 
ND ND 
ND ND 
ND ND 
ND ND 
c c 
c c 
ND ND 
+ 
-
+ -
+ -
+ c 
+ c 
+ c 
+ -
+ -
- -
+ c 
ND ND 
+ -
- c 
- -
M 
-
+ 
ND 
ND 
-
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
ND 
c 
c 
ND 
c 
c 
c 
c 
c 
c 
c 
c 
-
c 
ND 
c 
c 
-
0\ 
w 
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Cow 243 245 251 
T K R M T K R M T K R M 
Blood 
- - - - - - - - - - - -
Vaginal Swab c - - - + + + + c - - -
Parotid LN + + - + + + - - + + - + 
Prescapular LN 
- - - - - - - - - - -
-
Supramammary LN 
- - - - + + - + - - - + 
Hepatic LN - - - - + - - + c - - -
Int. Iliac LN 
- - - - - - - - - - - -
Mandibular LN + + - - - - - - + + - -
Bronchial LN + + - + + + - - - - - -
Retropharyngeal LN + - - - - - - - - - - -
Mammary Gland A c - - - + - - - - - - -
Mammary Gland B c - - - + + - + - - - -
Mammary Gland C c - - - c + - + - - - -
Mammary Gland D 
- - - -
c + - - - - - -
Placenta 
- - - - + + - + - - - -
Placetome 
- - - - + + - + - - - -
Uterus ND ND ND ND ND ND ND ND ND ND ND ND 
Colostrum Cream LF - - - - c + - - c - - -
Colostrum Sediment LF ND ND ND ND c - - - ND ND ND ND 
Colostrum Cream LR - - - - + + - + c - - -
Colostrum Sediment LR ND ND ND ND c + - + ND ND ND ND 
Colostrum Cream RF c - - - c + - - c - - -
Colostrum Sediment RF ND ND ND ND c + - + ND ND ND ND 
Colostrum Cream RR + + - + - - - - c - - -
Colostrum Sediment RR ND ND ND ND - - - - ND ND ND ND 
Calf 
Blood - - - - - - - - - - - -
Rectal Swab c - - - c + c c - - - -
Abomasol Fluid c 
- - -
c c - - - - - -
Liver - - - - - - - - - - - -
Lung - - - - c + c c - - - -
Spleen 
- - - - - - - - - - - -
T/K/R/M = TSA/Modified Kuzdas and Morse medium/Rifampin medium/Malachite Green medium 
(+)=Bruce/la abortus 2308; (-)=negative; C =contaminated; ND= not done 
252 
T K R M 
- - - -
+ + + + 
ND ND ND ND 
ND ND ND ND 
ND ND ND ND 
ND ND ND ND 
ND ND ND ND 
ND ND ND ND 
ND ND ND ND 
ND ND ND ND 
ND ND ND ND 
ND ND ND ND 
ND ND ND ND 
ND ND ND ND 
ND ND ND ND 
ND ND ND ND 
ND ND ND ND 
+ - - + 
+ - - -
+ + - + 
+ - - -
+ + - + 
- + - -
+ + - + 
+ + - + 
- - - -
c c - + 
c c c + 
- - - -
- - - -
- - - -
253 
T K R 
- - -
c c -
- - -
- - -
- - -
- - -
- - -
- - -
- - -
- - -
- - -
- - -
- - -
- - -
c - -
- - -
ND ND ND 
c - -
ND ND ND 
- - -
ND ND ND 
- - -
ND ND ND 
c 
- -
ND ND ND 
- - -
- - -
- - -
- - -
- - -
- - -
M 
-
c 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
ND 
-
ND 
-
ND 
-
ND 
-
ND 
-
-
-
-
-
-
O'I 
~ 
